performed RNAi screening and identified FBXO7 as a critical regulator of mesenchymal phenotype and immune evasion in breast cancer.[15] They found that several EMT‐related pathways, including TGF‐β receptor and MAPK signaling, are positively correlated with FBXO7 expression in cancers.[15] Although EMT in breast cancer has different characteristics from the PN‐MES transition in GBM, our findings consistently support a requirement of FBXO7 in maintaining MES phenotype. This evidence concerns the gene FBXO7 and glioblastoma.